Identification of Pro-Inflammatory Cytokines Associated with Muscle Invasive Bladder Cancer; The Roles of IL-5, IL-20, and IL-28A

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Lee, Se Jung ^a,b,f   Lee, Eo Jin ^a,f   Kim, Seon Kyu ^g   Jeong, Pildu ^f   Cho, Young Hwa ^c   Yun, Seok Joong ^f   Kim, Sangtae ^a   Kim, Gi Young ^d   Choi, Yung Hyun ^e   Cha, Eun Jong ^h   Kim, Wun Jae ^f   Moon, Sung Kwon ^a,f  

^a Chungju National University   (South Korea)

^b Chung Ang University   (South Korea)

^c Juseong College   (South Korea)

^d Jeju National University   (South Korea)

^e Dong Eui University   (South Korea)

^f Chungbuk National University College of Medicine   (South Korea)

^g Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^h Chungbuk National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD8ALPHA ANTIGEN; COMPLEMENTARY DNA; GELATINASE A; GELATINASE B; HLA DP ANTIGEN; HLA DPA1 ANTIGEN; HLA DPB1 ANTIGEN; HLA DQA1 ANTIGEN; HLA DR ANTIGEN; HLA DRB4 ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10 RECEPTOR ALPHA; INTERLEUKIN 11 RECEPTOR ALPHA; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 22 RECEPTOR ALPHA; INTERLEUKIN 26; INTERLEUKIN 28A; INTERLEUKIN 5; INTERLEUKIN 7 RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; STAT PROTEIN; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 7; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGED; ARTICLE; B2M GENE; BCL2 GENE; BLADDER CANCER; CANCER CELL; CANCER GENETICS; CANCER INVASION; CCL14 GENE; CD8A GENE; CELL MIGRATION; CFD GENE; CFH GENE; CFI GENE; CLEC10A GENE; CONTROLLED STUDY; CXCL12 GENE; ENZYME ACTIVATION; ENZYME ACTIVITY; FCER1A GENE; FEMALE; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC REGULATION; HLA DPA1 GENE; HLA DPB1 GENE; HLA DQA1 GENE; HLA DRA GENE; HLA DRB4 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IL10RA GENE; IL11RA GENE; IL15 GENE; IL16 GENE; IL17RB GENE; IL17RE GENE; IL18R1 GENE; IL18RAP GENE; IL1F5 GENE; IL1RAPL1 GENE; IL20 GENE; IL22RA1 GENE; IL26 GENE; IL28RA1 GENE; IL5 GENE; IL6ST GENE; IL7 GENE; IL7R GENE; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; MUSCLE INVASIVE BLADDER CANCER; NON MUSCLE INVASIVE BLADDER CANCER; NUCLEOTIDE SEQUENCE; ONCOGENE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TLR3 GENE; TLR7 GENE; TRAF2 GENE; WOUND HEALING;

AGED; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-5; INTERLEUKINS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84866010102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040267     Document Type: Article

References (62)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al.(2007) Cancer statistics. CA Cancer J Clin 57: 43-66.
2. Landis SH, Murray T, Bolden S, Wingo PA, (1999) Cancer Statistics. CA Cancer J Clin 49: 8-31.
3. Shen Z, Shen T, Wientjes MG, O'Donnell MA, Au JL, (2008) Intravesical treatments of bladder cancer: review. Pharm Res 25(7): 1500-1510.
4. Black PC, Dinney CP, (2007) Bladder cancer angiogenesis and metastasis-translation from murine model to clinical trial. Cancer Metastasis Rev 26(3-4): 623-34.
5. Morales A, Eidinger D, Bruce AW, (1976) Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116: 180-183.
6. Alexandroff AB, Jackson AM, O'Donnell MA, James K, (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353: 1689-1694.
7. Böhle A, Brandau S, (2003) Immune mechanisms in bacillus Calmette-Guérin immunotherapy for superficial bladder cancer. J Urol 170: 964-969.
8. Mitra AP, Bartsch CC, Cote RJ, (2009) Strategies for molecular expression profiling in bladder cancer. Cancer Metastasis Rev 28(3-4): 317-326.
9. Saban MR, Hellmich HL, Turner M, Nguyen NB, Vadigepalli R, et al.(2006) The inflammatory and normal transcriptome of mouse bladder detrusor and mucosa. BMC Physiol 6: 1-20.
10. Rathcke CN, Vestergaard H, (2006) YKL-40 a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res 55(6): 221-227.
11. Brumatti G, Salmanidis M, Ekert PG, (2010) Crossing paths: interactions between the cell death machinery and growth factor survival signals. Cell Mol Life Sci 67(10): 1619-1630.
12. Li CG, Li ML, Shu XH, Liu YJ, Wu WS, (2010) Antitumor effects of recombinant human interleukin-6 on mouse bladder carcinoma through Fas-mediated apoptosis. Cancer Chemother Pharmacol 66(5): 981-986.
13. Matsumoto K, Kikuchi E, Horinaga M, Takeda T, Miyajima A, et al.(2011) Intravesical Interleukin-15 Gene Therapy in an Orthotopic Bladder Cancer Model. Hum Gene Ther 22(11): 1423-1432.
14. Okamoto M, Hattori K, Oyasu R, (1997) Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int J Cancer 72(1): 149-154.
15. Inoue K, Slaton JW, Kim SJ, Perrotte P, Eve BY, et al.(2000) Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. Cancer Res 60(8): 2290-2299.
16. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, et al.(2009) IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206(7): 1457-64.
17. Tyagi P, Barclay D, Zamora R, Yoshimura N, Peters K, et al.(2009) Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study. Int Urol Nephrol.
18. Bouchelouche K, Alvarez S, Horn T, Nordling J, Bouchelouche P, (2006) Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha. Urology 67: 214-219.
19. Satyam A, Singh P, Badjatia N, Seth A, Sharma A, (2011) A disproportion of TH1/TH2 cytokines with predominance of TH2, in urothelial carcinoma of bladder. Urol Oncol 29(1): 58-65.
20. Wegenka UM, (2010) IL-20: biological functions mediated through two types of receptor complexes. Cytokine Growth Factor Rev 21(5): 353-363.
21. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al.(2003) IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69-77.
22. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, et al.(2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63-68.
23. Gaffen SL, (2011) Recent advances in the IL-17 cytokine family. Curr Opin Immunol 23(5): 613-619.
24. Garlanda C, Anders HJ, Mantovani A, (2009) TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 30(9): 439-446.
25. Davies B, Waxman J, Wasan H, Abel P, Williams G, et al.(1993) Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53: 5365-5369.
26. Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, et al.(1998) Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58: 1395-1399.
27. Bianco FJ Jr, Gervasi DC, Tiguert R, Grignon DJ, et al.(1998) Matrix metalloproteinase- 9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clin Cancer Res 4: 3011-3016.
28. Sier CF, Casetta G, Verheijen JH, Tizzani A, Agape V, et al.(2000) Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early stage bladder carcinoma: A comparison with clinically used tumor markers. Clin Cancer Res 6: 2333-2340.
29. Gerhards S, Jung K, Koenig F, Daniltchenko D, Hauptmann S, et al.(2001) Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. Urology 57: 675-679.
30. Huhtala P, Chow L, Trygvason K, (1990) Structure of the human type IV collagenase gene. J Biol Chem 265: 11077-11082.
31. Sato H, Kita M, Seiki M, (1993) v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem 268: 23460-23468.
32. Sato H, Seiki M, (1993) Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8: 395-405.
33. Adachi T, Alam R, (1998) The mechanism of IL-5 signal transduction. Am J Physiol 275(3 Pt 1): C623-C633.
34. Takatsu K, Nakajima H, (2008) IL-5 and eosinophilia. Curr Opin Immunol 20(3): 288-294.
35. Pazdrak K, Schreiber D, Forsythe P, Justement L, Alam R, (1995) The signal transduction mechanism of IL-5 in eosinophils: the involvement of lyn tyrosine kinase and the ras-raf 1-MEK-MAP kinase pathway. J Exp Med 181: 1827-1834.
36. Pazdrak K, Stafford S, Alam R, (1995) The activation of the Jak-STAT1 signaling pathway by IL-5 in eosinophils. J Immunol 155: 397-402.
37. Yousefi S, Hoessli DC, Blaser K, Mills GB, Simon HU, (1996) Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokine in human eosinophils. J Exp Med 183: 1407-1414.
38. Coffer PJ, Schweizer RC, Dubois GR, Maikoe T, Lammers JJ, et al.(1998) Analysis of signal transduction pathways in human eosinophils activated by chemoattractants and the T-helper-2-derived cytokines interleukin-4 and interleukin-5. Blood 91: 2547-2557.
39. Sato S, Katagiri T, Takaki S, Kikuchi Y, Hitoshi Y, et al.(1994) IL-5 receptor-mediated tyrosine phosphorylation of SH2/SH3-containing proteins and activation of Bruton's tyrosine and Janus 2 kinases. J Exp Med.
40. Takatsu K, Kouro T, Nagai Y, (2009) Interleukin 5 in the link between the innate and acquired immune response. Adv Immunol 101: 191-236.
41. Lee CF, Chang SY, Hsieh DS, Yu DS, (2004) Immunotherapy for bladder cancer using recombinant bacillus Calmette-Guerin DNA vaccines and interleukin-12 DNA vaccine. J Urol Mar 171(3): 1343-1347.
42. Blumberg H, Conklin D, Xu WF, Grossmann A, Brender T, et al.(2001) Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell 104(1): 9-19.
43. Xu W, (2004) Interleukin-20. Int Immunopharmacol. 4(5): 627-633.
44. Hsieh MY, Chen WY, Jiang MJ, Cheng BC, Huang TY, et al.(2006) Interleukin-20 promotes angiogenesis in a direct and indirect manner. Genes Immuno 7(3): 234-242.
45. Chen WY, Chang MS, (2009) IL-20 is regulated by hypoxia-inducible factor and up-regulated after experimental ischemic stroke. J Immunol 182(8): 5003-5012.
46. Li M, Liu X, Zhou Y, Su SB, (2009) Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 86(1): 23-32.
47. Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, et al.(2005) IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression. Am J Physiol Gastrointest Liver Physiol 289: G960-G968.
48. Zhu H, Butera M, Nelson DR, Liu C, (2005) Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J 2: 80.
49. Zitzmann K, Brand S, Baehs S, Goke B, Meinecke J, et al.(2006) Novel interferon-λs induce antiproliferative effects in neuroendocrine tumor cells. Biochem. Biophys Res Commun 344: 1334-1341.
50. Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, et al.(2006) Characterization of the mouse IFN-λ ligand-receptor system: IFN-λs exhibit antitumor activity against B16 melanoma. Cancer Res 66: 4468-4477.
51. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, et al.(2007) IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol 178: 5086-5098.
52. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T, (2006) Antitumor activity of IFN-λ in murine tumor models. J Immuno. 176: 7686-7694.
53. Matrisian LM, (1990) Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6(4): 121-125.
54. Liotta LA, (1986) Tumor invasion and metastasis-role of extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res 46: 1-7.
55. Dranoff G, (2004) Cytokines in cancer pathogenesis and cancer therapy. Nature Rev 4: 12-22.
56. Goswami B, Rajappa M, Sharma M, Sharma A, (2008) Inflammation: Its role and interplay in the development of cancer, with special focus on gynecological malignancies. Int J Gynecol Cancer18: 591-599.
57. Kim WJ, Kim EJ, Kim SK, Kim YJ, Ha YS, et al.(2010) Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. Mol Cancer 9: 3-11.
58. Eisen MB, Spellman PT, Brown PO, Botstein D, (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.
59. Wright GW, Simon RM, (2003) A random variance model for detection of differential gene expression in small microarray experiments. Bioinformatics 19: 2448-2455.
60. Moon SK, Cha BY, Kim CH, (2004) ERK1/2 mediates TNF-alpha-induced matrix metalloproteinase-9 expression in human vascular smooth muscle cells via the regulation of NF-kappaB and AP-1: Involvement of the ras dependent pathway. J Cell Physiol 198(3): 417-427.
61. Yoon TJ, Yu KN, Kim E, Kim JS, Kim BG, et al.(2006) Specific Targeting, Cell Sorting, and Bioimaging with Smart Magnetic Silica Core-Shell Nanomaterials. Small 2(2): 209-215.
62. So MK, Loening AM, Gambhir SS, Rao J, (2006) Creating self-illuminating quantum dot conjugates. Nat Protoc 1(3): 1160-1164.